Company / Cash & Equivalents
Baxter International Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$2.0B
FY2025
5-year range
$1.6B / $3.1B
FY2021-FY2025
Trend
+11.5%
vs FY2024
Sector context
#20 of 148
Health Care
What the data says
Baxter International's cash & equivalents of $2.0B is higher than 86% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $1.6B in FY2022 to $3.7B in FY2020.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of -12.0%. Top quartile in the Health Care sector.
Declined from $3.1B to $2.0B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +6.6%
- 5-Year CAGR
- -12.0%
- 10-Year CAGR
- -
Sector benchmark
+67.1% above sector average
Key checks
Key Insights
- 5-year CAGR of -12.0%, indicating a declining trend.
- In FY2025, cash & equivalents increased 11.5% year-over-year.
- Ranks #20 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Negative profit margin: -6.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +11.5% |
| FY2024 | $1.8B | -42.7% |
| FY2023 | $3.1B | +89.9% |
| FY2022 | $1.6B | -45.1% |
| FY2021 | $3.0B | -20.9% |
| FY2020 | $3.7B | +11.8% |
| FY2019 | $3.3B | +13.1% |
| FY2018 | $2.9B | -13.1% |
| FY2017 | $3.4B | +16.0% |
| FY2016 | $2.9B | +32.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026